All sponsors

Shandong New Time Pharmaceutical Co., LTD

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-36
RECRUITING4
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO0%

Delay Index: of 5 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Shandong New Time Pharmaceutical Co., LTD on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Phase III
NCT06819774
P3RecruitingAcute Urticaria2842025-08
CAPEOX
NCT06722950
P2Not yet recruitingColorectal Adenoma1202026-12
Vonorasan fumarate injection1
NCT06783257
P2Not yet recruitingPeptic Ulcer Bleeding1502027-02
Valsartan Oral Solution
NCT06863987
P3Enrolling by invitationEssential Hypertension3422027-12
F520 combined with chemotherapy
NCT07761429
P2/3RecruitingCancer of Unknown Primary Site4022027-12-30
F182112+P
NCT07312188
P2RecruitingRelapsed or Refractory Multiple Myeloma902028-05-20
F027
NCT07046273
P3Not yet recruitingType 2 Diabetes (T2DM)4962028-08-01
Rulonilimab
NCT06755515
P2/3Enrolling by invitationCervical Cancer5102028-09
F182112 single-agent
NCT07579234
P3RecruitingRelapsed or Refractory Multiple Myeloma (RRMM)2612029-01-25